Today Bayer (ETR:BAYN) Has Been Upgraded by HSBC to a Buy


Bayer (ETR:BAYN) Stock Upgrade

Trading for shares of Bayer (ETR:BAYN) will be watched closely today, as HSBC upgraded the stock to a solid rating of a Buy. In addition to their ratings upgrade, HSBC set a Estimated Target Price of EUR 138.00 which was 20.16% higher.

From a total of 18 analysts covering Bayer (ETR:BAYN) stock, 9 rate it a ”Buy”, 0 a “Sell”, and 9 a ”Hold”. This means that 50% of the ratings are positive. The highest target price is €160 while the lowest target price is €121. The mean of all analyst targets is €141.91 with a 23.72% above today’s (€114.7) stock price. Bayer was the topic of 54 analyst reports since July 22, 2015 according to the firm StockzIntelligence Inc. Equinet maintained shares on December 10 with “Neutral” rating. Credit Suisse upgraded shares to “Outperform” rating and €135 target share price in a report from a November 17. Jefferies maintained BAYN stock in a recent report from December 8 with “Hold” rating. Bernstein upgraded the rating on November 13. Bernstein has a “Outperform” rating and a €152 price target on shares. Finally, Deutsche Bank upgraded the stock to “Buy” rating in a report issued on a December 1.

The stock increased 0.97% or EUR 1.1 on December 10, striking EUR 114.7. Approximately 2.23M shares of stock traded hands or 25.28% up from the average. Bayer AG (ETR:BAYN) has 0.00% since May 14, 2015 and is . It has outperformed by 1.93% the S&P500.

 Today Bayer (ETR:BAYN) Has Been Upgraded by HSBC to a Buy

Bayer AG is a strategic management holding company. The company has a market cap of 96.85 billion EUR. The Company’s business are organized into three subgroups: Bayer HealthCare, Bayer CropScience and Bayer MaterialScience, supported by the service companies Bayer Business Services, Bayer Technology Services and Currenta. It has 26.04 P/E ratio. Bayer HealthCare researches, develops, makes and markets products to improve the health of people and animals.